Evidence map›Paper›PMID 37280482›Full record

ReviewCerebellum (London, England)2024

MR Imaging in Ataxias: Consensus Recommendations by the Ataxia Global Initiative Working Group on MRI Biomarkers.

Gülin Öz, Sirio Cocozza, Pierre-Gilles Henry, Christophe Lenglet, Andreas Deistung, Jennifer Faber, Adam J Schwarz, Dagmar Timmann, Koene R A Van Dijk, Ian H Harding and 1 more

Erratum issuedOpen access · hybridAbstract readReviewConsensus Statement
In one paragraph

Review in Cerebellum (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Neural Correlates of Intellectual Dysfunction in Episodic Ataxia Type 2.Journal of clinical neurology (Seoul, Korea) · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 4 countries.

Gülin ÖzCenter for Magnetic Resonance Research, Department of Radiology, University of Minnesota, 2021 Sixth Street Southeast, Minneapolis, MN, 55455, USA. gulin@cmrr.umn.edu.
Sirio CocozzaUNINA Department of Advanced Biomedical Sciences, University of Naples Federico II , Naples, Italy.
Pierre-Gilles HenryCenter for Magnetic Resonance Research, Department of Radiology, University of Minnesota, 2021 Sixth Street Southeast, Minneapolis, MN, 55455, USA.
Christophe LengletCenter for Magnetic Resonance Research, Department of Radiology, University of Minnesota, 2021 Sixth Street Southeast, Minneapolis, MN, 55455, USA.
Andreas DeistungDepartment for Radiation Medicine, University Clinic and Outpatient Clinic for Radiology, University Hospital Halle (Saale), Halle (Saale), Germany.
Jennifer FaberGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Adam J SchwarzTakeda Pharmaceuticals Ltd., Cambridge, MA, USA.
Dagmar TimmannDepartment of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Essen University Hospital, University of Duisburg-Essen, Essen, Germany.
Koene R A Van DijkDigital Sciences and Translational Imaging, Early Clinical Development, Pfizer, Inc., Cambridge, MA, USA.
Ian H HardingDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia.
AGI Working Group on MRI Biomarkers
University of Minnesota · USUniversity Hospital in Halle · DEEssen University Hospital · DEMonash University · AUPfizer (United States) · USTakeda (United States) · USUniversity Hospital Bonn · DEUniversity of Naples Federico II · IT

Funding

Supplementary funding for U01NS104326 Clinical Trial Readiness for SCA1 and SCA3 (“READISCA”)U01NS104326 · NINDS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI ASHIZAWA, TETSUO, DURR, ALEXANDRA · 2018 to 2022
$6.1M
Deciphering the Role of the Pumilio1 in Two Distinct Neurological DiseasesR01NS109858 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Vincenzo Alessandro Gennarino · 2019 to 2026
$4.1M
Partnership for Magnetic Resonance Spectroscopy Biomarker Development-SupplementR01NS080816 · NINDS · UNIVERSITY OF MINNESOTA · PI OZ, GULIN · 2015 to 2019
$3.2M
NINDS NIH HHS R01 NS080816NINDS NIH HHS R01 NS109858NINDS NIH HHS U01 NS104326NINDS NIH HHS U01 NS104326, R01 NS080816
6 · The paper itself

Abstract

With many viable strategies in the therapeutic pipeline, upcoming clinical trials in hereditary and sporadic degenerative ataxias will benefit from non-invasive MRI biomarkers for patient stratification and the evaluation of therapies. The MRI Biomarkers Working Group of the Ataxia Global Initiative therefore devised guidelines to facilitate harmonized MRI data acquisition in clinical research and trials in ataxias. Recommendations are provided for a basic structural MRI protocol that can be used for clinical care and for an advanced multi-modal MRI protocol relevant for research and trial settings. The advanced protocol consists of modalities with demonstrated utility for tracking brain changes in degenerative ataxias and includes structural MRI, magnetic resonance spectroscopy, diffusion MRI, quantitative susceptibility mapping, and resting-state functional MRI. Acceptable ranges of acquisition parameters are provided to accommodate diverse scanner hardware in research and clinical contexts while maintaining a minimum standard of data quality. Important technical considerations in setting up an advanced multi-modal protocol are outlined, including the order of pulse sequences, and example software packages commonly used for data analysis are provided. Outcome measures most relevant for ataxias are highlighted with use cases from recent ataxia literature. Finally, to facilitate access to the recommendations by the ataxia clinical and research community, examples of datasets collected with the recommended parameters are provided and platform-specific protocols are shared via the Open Science Framework.

Indexed as

AtaxiaBiomarkersMagnetic Resonance ImagingBrainHumansBiomarkersDiffusion MRIFunctional MRIMagnetic resonance spectroscopyMRI biomarkersQuantitative susceptibility mappingStructural MRI

Identifiers

PMID37280482
PMCPMC11102392
OpenAlexW4379535187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.